Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Clinical trial NCT02216409 · COMPLETED
Trial details
- NCT number
- NCT02216409
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-01
- Primary completion
- 2018-10-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.